• Modeling Mechanism：

  As a core myelin autoantigen, PLP(190-209) exerts its modeling mechanism as follows: ① Binds to MHC class II molecules (H-2k) of C3H/HeJ mice, activating myelin-specific CD4⁺ T cells that escape peripheral immune tolerance, leading to increased expression of activation markers (elevated CD25⁺, decreased CD62L⁺); ② Activated autoreactive T cells cross the blood-brain barrier, infiltrate the central nervous system (CNS), mainly accumulate in the spinal cord (predominantly lumbosacral segments), and secrete pro-inflammatory cytokines such as IFN-γ and IL-17; ③ Recruits immune cells such as macrophages (CD11b⁺ cells) to form inflammatory foci, triggering demyelination and axonal damage in the spinal cord white matter, ultimately leading to ascending paralysis, which mimics the core pathological process of human multiple sclerosis (MS).

• Related Products：

  PLP (190-209) (TP2616)

• Modeling Method：

  Experimental Subject：

  Mice, C3H/HeJ, Female, 10-12 weeks old, SPF-grade feeding (ad libitum access to food and water, standard environmental conditions)

  Dosage and Administration Route：

  ① Core modeling: PLP(190-209) 100 μg/mouse+Mycobacterium tuberculosis 400 μg/mouse, emulsified in Complete Freund's Adjuvant (CFA), subcutaneous injection in the back; ② Adjunctive modeling: Pertussis Toxin (PTX) 400 ng/mouse, intraperitoneal injection, once on the day of modeling and once on day 2 post-modeling; ③ Control treatment: Subcutaneous injection of CFA+physiological saline emulsion+intraperitoneal injection of equal volume of PTX;

  Dosing Frequency and Duration Model：

  Single subcutaneous injection of PLP(190-209)+two intraperitoneal injections of PTX

• Validation：

  1. Behavioral indicators (core validation): - Clinical scoring: Using a 0-10 point scoring system, the average score reaches 4.8±1.0 on day 35 post-modeling, manifested as ascending paralysis (limp tail → hindlimb weakness → paraplegia, some progressing to quadriplegia), with a disease incidence of approximately 60%; - Body weight change: Body weight starts to decrease on day 22.8±0.3, with a maximum weight loss of 14% at the peak; 2. Immune indicators: - Peripheral immunity: Splenic lymphocytes show significantly increased proliferative activity after in vitro stimulation with PLP(190-209) (strongest proliferation at 100 μg/mL concentration), with increased secretion of IFN-γ and IL-17; - CNS immune infiltration: Increased infiltration of CD4⁺ T cells, CD8⁺ T cells, and CD11b⁺ macrophages in spinal cord tissue; 3. Pathological indicators: - Inflammatory foci: The area affected by inflammation in the lumbosacral segment of the spinal cord reaches 39.26±2.64%, 8.37±2.36% in the thoracic segment, and mild inflammation in the brain parenchyma; - Demyelination: Luxol Fast Blue (LFB) staining shows demyelination in the spinal cord white matter, consistent with the distribution of inflammatory foci; 4. Molecular indicators: Increased expression of T cell activation marker CD25⁺ and decreased expression of CD62L⁺ (p<0.001).

*Precautions：

*References：Göbel K,et,al. Active immunization with proteolipid protein (190-209) induces ascending paralysing experimental autoimmune encephalomyelitis in C3H/HeJ mice. J Immunol Methods. 2011 Mar 31;367(1-2):27-32.